NCT07192666尚未招募1 期
Exploratory Clinical Trial of Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome
Guangdong ProCapZoom Biosciences Co., Ltd.0 个研究点目标入组 12 人开始时间: 2025年9月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
- 主要终点
- Adverse events (AEs)
研究概览
简要总结
This study is a single-center, multiple-dosing, prospective, nonrandom, single-arm trial.
详细描述
This study is a single-center, multiple-dosing, prospective, nonrandom, single-arm trial. To evaluate the clinical safety and efficacy of exosomes in patients with ocular involvement of Sjögren's syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-65 years old, including the boundary value, no gender restriction;
- •Subjects meeting the 2016 ACR/EULAR classification criteria for Sjögren's syndrome, and also meet the diagnostic criteria for ocular involvement.
- •The ocular involvement symptoms and signs of these patients cannot be relieved after at least 3 months of conventional therapy, including artificial tears and topical or systemic corticosteroids.
- •Extra-ocular manifestations of Sjögren's syndrome clinically stable.
- •Subjects and their partners agree to use effective non-pharmacological contraception from screening through 6 months after the last dose and have no plans for conception during this period.
- •Willing to participate in the study, understand and sign the informed consent form (ICF).
排除标准
- •Known allergy to any component of the investigational drug.
- •Active ocular infection.
- •Presence of other significant ocular disease or trauma diagnosed prior to enrollment, including but not limited to glaucoma, uveitis, retinopathy, chemical injury, or thermal burns.
- •History of any ocular surgery within the preceding 6 months, including cataract surgery.
- •Participation in another interventional clinical study.
- •Use of any ophthalmic medication that may interfere with the study outcomes, such as other stem-cell-derived products.
- •Having serious underlying diseases of the heart, brain vessels, liver, kidneys, and hematopoietic system.
- •Pregnant or lactating women; women of childbearing potential must employ an effective contraceptive method (e.g., intrauterine device, oral contraceptive, or condom) during the study and for at least 3 months after the final dose of study drug.
- •Subjects deemed unsuitable for participation in this trial by the investigator.
研究组 & 干预措施
Exosome Preparation Group
Experimental
Each subject will have a single designated study eye; this eye will receive multiple instillations-one drop four times daily for 14 consecutive days.
干预措施: Exosome Preparation (Drug)
结局指标
主要结局
Adverse events (AEs)
时间窗: from subjects receiving administration to Day 29 post-administration
Incidence and severity of adverse events (AEs) from subjects receiving administration to Day 29 post-administration.
次要结局
- TBUT(from baseline on Day 8, Day 15 and Day 29 post-administration)
- CFS(from baseline to Day 8, Day 15 and Day 29 post-administration)
- OSDI(from baseline on Day 8, Day 15 and Day 29 post-administration)
- Schirmer's test(from baseline on Day 8, Day 15 and Day 29 post-administration)
研究者
相似试验
尚未招募
1 期
MSCohi-O Lenses for Ocular Involvement in Sjögren's SyndromeSjögren's SyndromeNCT07185139Guangdong ProCapZoom Biosciences Co., Ltd.12
已完成
不适用
A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation SystemMenorrhagia Due to Benign CausesNCT02029911Minerva Surgical, Inc.63
已完成
不适用
Jetstream in Treatment of Occlusive Atherosclerotic Lesions in the SFA and/or PPAAtherosclerosisNCT03455855Boston Scientific Corporation72
进行中（未招募）
4 期
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic PainChronic, Intractable Back Pain and/or Leg PainNCT06897280Nevro Corp25
已完成
2 期
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgeryDonafenibOxaliplatinCarcinomaCarcinoma, HepatocellularLiver NeoplasmsDigestive System NeoplasmsFluorouracilAntimetabolitesAntineoplastic AgentsNCT04962958Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University30